{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:07:37Z","timestamp":1774519657535,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T00:00:00Z","timestamp":1590019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Hepatitis D virus (HDV) infection may induce fulminant hepatitis in chronic hepatitis B patients (CHB) or rapid progression of CHB to cirrhosis or hepatocellular carcinoma. There is no effective treatment for HDV infection. HDV encodes small delta antigens (S-HDAg) and large delta antigens (L-HDAg). S-HDAg is essential for HDV replication. Prenylated L-HDAg plays a key role in HDV assembly. Previous studies indicate that L-HDAg transactivates transforming growth factor beta (TGF-\u03b2) and induces epithelial-mesenchymal transition (EMT), possibly leading to liver fibrosis. However, the mechanism is unclear.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The mechanisms of the activation of <jats:italic>Twist<\/jats:italic> promoter by L-HDAg were investigated by luciferase reporter assay, chromatin immunoprecipitation, and co-immunoprecipitation analysis. ELISA and Western blotting were used to analyze L-HDAg prenylation, TGF-\u03b2 secretion, expression of EMT markers, and to evaluate efficacy of statins for HDV treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We found that L-HDAg activated Twist expression, TGF-\u03b2 expression and consequently induced EMT, based on its interaction with Smad3 on Twist promoter. The treatment of statin, a prenylation inhibitor, resulted in reduction of <jats:italic>Twist<\/jats:italic> promoter activity, TGF-\u03b2 expression, and EMT, and reduces the release of HDV virions into the culture medium.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>We demonstrate that L-HDAg activates EMT via Twist and TGF-\u03b2 activation. Treatment with statins suppressed Twist expression, and TGF-\u03b2 secretion, leading to downregulation of EMT. Our findings clarify the mechanism of HDV-induced EMT, and provide a basis for possible novel therapeutic strategies against HDV infection.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12929-020-00659-6","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T04:06:26Z","timestamp":1590033986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Statin inhibits large hepatitis delta antigen-Smad3 -twist-mediated epithelial-to-mesenchymal transition and hepatitis D virus secretion"],"prefix":"10.1186","volume":"27","author":[{"given":"Yuh-Jin","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Pu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-An","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi-Hua","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-3044","authenticated-orcid":false,"given":"Jaw-Ching","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,21]]},"reference":[{"issue":"6","key":"659_CR1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0016-5085(84)80153-5","volume":"86","author":"S Govindarajan","year":"1984","unstructured":"Govindarajan S, Chin KP, Redeker AG, Peters RL. Fulminant B viral hepatitis: role of delta agent. Gastroenterology. 1984;86(6):1417\u201320.","journal-title":"Gastroenterology."},{"issue":"4","key":"659_CR2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7326\/0003-4819-98-4-437","volume":"98","author":"M Rizzetto","year":"1983","unstructured":"Rizzetto M, Verme G, Recchia S, Bonino F, Farci P, Arico S, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med. 1983;98(4):437\u201341.","journal-title":"Ann Intern Med"},{"issue":"3","key":"659_CR3","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/0016-5085(95)90453-0","volume":"108","author":"JC Wu","year":"1995","unstructured":"Wu JC, Chen TZ, Huang YS, Yen FS, Ting LT, Sheng WY, et al. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology. 1995;108(3):796\u2013802.","journal-title":"Gastroenterology."},{"issue":"4","key":"659_CR4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0966-842X(03)00045-3","volume":"11","author":"JM Taylor","year":"2003","unstructured":"Taylor JM. Replication of human hepatitis delta virus: recent developments. Trends Microbiol. 2003;11(4):185\u201390.","journal-title":"Trends Microbiol"},{"issue":"12","key":"659_CR5","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1128\/JVI.69.12.7593-7600.1995","volume":"69","author":"JL Casey","year":"1995","unstructured":"Casey JL, Gerin JL. Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA. J Virol. 1995;69(12):7593\u2013600.","journal-title":"J Virol"},{"issue":"9","key":"659_CR6","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3201\/eid1209.060112","volume":"12","author":"F Le Gal","year":"2006","unstructured":"Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis. 2006;12(9):1447\u201350.","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"659_CR7","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/j.gastro.2006.01.035","volume":"130","author":"CW Su","year":"2006","unstructured":"Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology. 2006;130(6):1625\u201335.","journal-title":"Gastroenterology."},{"issue":"8980","key":"659_CR8","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(95)91558-3","volume":"346","author":"JC Wu","year":"1995","unstructured":"Wu JC, Choo KB, Chen CM, Chen TZ, Huo TI, Lee SD. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet. 1995;346(8980):939\u201341.","journal-title":"Lancet."},{"issue":"5","key":"659_CR9","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1128\/JVI.02155-07","volume":"82","author":"HH Shih","year":"2008","unstructured":"Shih HH, Jeng KS, Syu WJ, Huang YH, Su CW, Peng WL, et al. Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus. J Virol. 2008;82(5):2250\u201364.","journal-title":"J Virol"},{"issue":"17","key":"659_CR10","doi-asserted-by":"crossref","first-page":"9044","DOI":"10.1128\/JVI.00130-12","volume":"86","author":"HH Shih","year":"2012","unstructured":"Shih HH, Sheen IJ, Su CW, Peng WL, Lin LH, Wu JC. Hepatitis D virus isolates with low replication and epithelial-mesenchymal transition-inducing activity are associated with disease remission. J Virol. 2012;86(17):9044\u201354.","journal-title":"J Virol"},{"issue":"14","key":"659_CR11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJM199104043241401","volume":"324","author":"A Castilla","year":"1991","unstructured":"Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med. 1991;324(14):933\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"659_CR12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2006.10.038","volume":"132","author":"SH Choi","year":"2007","unstructured":"Choi SH, Jeong SH, Hwang SB. Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: implication of hepatitis delta virus-induced liver fibrosis. Gastroenterology. 2007;132(1):343\u201357.","journal-title":"Gastroenterology."},{"issue":"37","key":"659_CR13","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1038\/sj.onc.1208927","volume":"24","author":"J Zavadil","year":"2005","unstructured":"Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005;24(37):5764\u201374.","journal-title":"Oncogene."},{"issue":"3","key":"659_CR14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"659_CR15","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/hep.23221","volume":"50","author":"MH Yang","year":"2009","unstructured":"Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology. 2009;50(5):1464\u201374.","journal-title":"Hepatology."},{"issue":"9785","key":"659_CR16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(10)61931-9","volume":"378","author":"SA Hughes","year":"2011","unstructured":"Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378(9785):73\u201385.","journal-title":"Lancet."},{"issue":"11","key":"659_CR17","doi-asserted-by":"crossref","first-page":"9303","DOI":"10.1128\/JVI.72.11.9303-9306.1998","volume":"72","author":"JS Glenn","year":"1998","unstructured":"Glenn JS, Marsters JC Jr, Greenberg HB. Use of a prenylation inhibitor as a novel antiviral agent. J Virol. 1998;72(11):9303\u20136.","journal-title":"J Virol"},{"issue":"20","key":"659_CR18","doi-asserted-by":"crossref","first-page":"10465","DOI":"10.1128\/JVI.76.20.10465-10472.2002","volume":"76","author":"BB Bordier","year":"2002","unstructured":"Bordier BB, Marion PL, Ohashi K, Kay MA, Greenberg HB, Casey JL, et al. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol. 2002;76(20):10465\u201372.","journal-title":"J Virol"},{"key":"659_CR19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev.bi.65.070196.001325","volume":"65","author":"FL Zhang","year":"1996","unstructured":"Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241\u201369.","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"659_CR20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1172\/JCI0216421","volume":"110","author":"JK Liao","year":"2002","unstructured":"Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 2002;110(3):285\u20138.","journal-title":"J Clin Invest"},{"issue":"2","key":"659_CR21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/5587","volume":"5","author":"K Itoh","year":"1999","unstructured":"Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for rho-associated kinase in the transcellular invasion of tumor cells. Nat Med. 1999;5(2):221\u20135.","journal-title":"Nat Med"},{"issue":"3","key":"659_CR22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ncb1691","volume":"10","author":"MH Yang","year":"2008","unstructured":"Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol. 2008;10(3):295\u2013305.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"659_CR23","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ki.2015.121","volume":"88","author":"YB Sun","year":"2015","unstructured":"Sun YB, Qu X, Howard V, Dai L, Jiang X, Ren Y, et al. Smad3 deficiency protects mice from obesity-induced podocyte injury that precedes insulin resistance. Kidney Int. 2015;88(2):286\u201398.","journal-title":"Kidney Int"},{"issue":"13","key":"659_CR24","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/bioinformatics\/bti473","volume":"21","author":"K Cartharius","year":"2005","unstructured":"Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005;21(13):2933\u201342.","journal-title":"Bioinformatics."},{"issue":"3","key":"659_CR25","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3892\/or.2012.1860","volume":"28","author":"J Kah","year":"2012","unstructured":"Kah J, Wustenberg A, Keller AD, Sirma H, Montalbano R, Ocker M, et al. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep. 2012;28(3):1077\u201383.","journal-title":"Oncol Rep"},{"issue":"4","key":"659_CR26","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hep.1840060415","volume":"6","author":"S Govindarajan","year":"1986","unstructured":"Govindarajan S, De Cock KM, Redeker AG. Natural course of delta superinfection in chronic hepatitis B virus-infected patients: histopathologic study with multiple liver biopsies. Hepatology. 1986;6(4):640\u20134.","journal-title":"Hepatology."},{"issue":"10","key":"659_CR27","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","volume":"15","author":"C Koh","year":"2015","unstructured":"Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015;15(10):1167\u201374.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"659_CR28","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep.29658","volume":"67","author":"C Yurdaydin","year":"2018","unstructured":"Yurdaydin C, Keskin O, Kalkan C, Karakaya F, Caliskan A, Karatayli E, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV-1 study. Hepatology. 2018;67(4):1224\u201336.","journal-title":"Hepatology."},{"issue":"6","key":"659_CR29","first-page":"342","volume":"14","author":"P Farci","year":"2018","unstructured":"Farci P, Anna NG. Current and future Management of Chronic Hepatitis D. Gastroenterol Hepatol. 2018;14(6):342\u201351.","journal-title":"Gastroenterol Hepatol"},{"issue":"11","key":"659_CR30","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/ajg.2016.423","volume":"111","author":"YW Huang","year":"2016","unstructured":"Huang YW, Hsieh AC, Yang SS. Statins and the risk of cirrhosis and its Decompensation in chronic hepatitis B patients. Am J Gastroenterol. 2016;111(11):1655\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"659_CR31","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","volume":"15","author":"RG Kim","year":"2017","unstructured":"Kim RG, Loomba R, Prokop LJ, Singh S. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15(10):1521\u201330 e8.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"659_CR32","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jhep.2015.07.009","volume":"63","author":"JC Hsiang","year":"2015","unstructured":"Hsiang JC, Wong GL, Tse YK, Wong VW, Yip TC, Chan HL. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity score landmark analysis. J Hepatol. 2015;63(5):1190\u20137.","journal-title":"J Hepatol"},{"issue":"9","key":"659_CR33","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1128\/JVI.69.9.5332-5336.1995","volume":"69","author":"CZ Lee","year":"1995","unstructured":"Lee CZ, Chen PJ, Chen DS. Large hepatitis delta antigen in packaging and replication inhibition: role of the carboxyl-terminal 19 amino acids and amino-terminal sequences. J Virol. 1995;69(9):5332\u20136.","journal-title":"J Virol"},{"issue":"3","key":"659_CR34","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/JVI.65.3.1099-1104.1991","volume":"65","author":"JC Wu","year":"1991","unstructured":"Wu JC, Chen PJ, Kuo MY, Lee SD, Chen DS, Ting LP. Production of hepatitis delta virus and suppression of helper hepatitis B virus in a human hepatoma cell line. J Virol. 1991;65(3):1099\u2013104.","journal-title":"J Virol"},{"issue":"Pt 11","key":"659_CR35","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1099\/vir.0.011239-0","volume":"90","author":"V Williams","year":"2009","unstructured":"Williams V, Brichler S, Radjef N, Lebon P, Goffard A, Hober D, et al. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha\/beta interferon-inducible MxA gene. J Gen Virol. 2009;90(Pt 11):2759\u201367.","journal-title":"J Gen Virol"},{"issue":"3","key":"659_CR36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1172\/JCI17704","volume":"112","author":"BB Bordier","year":"2003","unstructured":"Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest. 2003;112(3):407\u201314.","journal-title":"J Clin Invest"},{"key":"659_CR37","doi-asserted-by":"crossref","first-page":"15259","DOI":"10.1038\/srep15259","volume":"5","author":"YM Shih","year":"2015","unstructured":"Shih YM, Sun CP, Chou HH, Wu TH, Chen CC, Wu PY, et al. Combinatorial RNA interference therapy prevents selection of pre-existing HBV variants in human liver chimeric mice. Sci Rep. 2015;5:15259.","journal-title":"Sci Rep"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-020-00659-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12929-020-00659-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12929-020-00659-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T23:11:19Z","timestamp":1621552279000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-020-00659-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,21]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["659"],"URL":"https:\/\/doi.org\/10.1186\/s12929-020-00659-6","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,21]]},"assertion":[{"value":"8 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable<b>.<\/b>","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}